 | FRI, JAN 17, 2020 | | | | It's a wrap for #JPM20 — What you should know | | | | Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.
Happy Friday.
The 38th J.P. Morgan Healthcare Conference has come to an end. This week we'll share what happened at the San Francisco event. It began with Novartis striking a deal Monday to provide its cholesterol drug to UK patients. But otherwise the conference seemed to lack the mega M&A deals it's known for. More on that later. Until next week, have a good one!
(Are there any stories we should be chasing? Email tips, ideas, suggestions to CNBC Health Editor Dawn Kopecki at dawn.kopecki@nbcuni.com.)
| | A slow news start to #JPM20, but still plenty to talk about | Biotech stocks sagged as the start of the year's largest health investing event didn't bring about the firehose of deal news and clinical trial results of years past. But there was still plenty to discuss. A brand new company was founded to undercut the price of drugs. Pfizer's new CEO Albert Bourla sat down with me for his first interview and shed some light on his plans for the pharma giant. And then there was Amber Freed, a mom who came to try to further her goal of getting a gene therapy developed to save her son, Maxwell.
-Meg Tirrell | | | | At JPM, execs wondered: What's digital health? | One question that came up frequently in conversations and panels at #JPM20: What is digital health? Investors have poured billions of dollars into the intersection of health and technology, but there's still a lack of understanding of what types of companies can be considered "digital health" and the problems they're trying to solve. Many agreed that the term has become so over-hyped and over-used that it's essentially meaningless.
-Chrissy Farr | | | | On panels and interviews, pharma CEOs pitch ideas for lowering drug costs | CEOs from the world's largest pharmaceutical companies pitched ideas for lowering drug prices at the conference. None, however, offered to cut prices on any of their own drugs. Regeneron CEO Leonard Schleifer suggested making changes to Medicare. Pfizer CEO Albert Bourla supported passing rebates paid to pharmacy benefit managers through to consumers. Bristol-Myers Squibb CEO Giovanni Caforio and Roche CEO Bill Anderson blasted hospitals for marking up the price of medicines. Not sure how those arguments will play out in Washington as the 2020 presidential election heats up.
-Berkeley Lovelace Jr. | | Healthy Returns: Investing in health care innovation
How innovators and investors are working with patients and providers to develop dynamic new solutions and create healthy returns.
CNBC presents a one-day event that brings together top health care investors, CEOs and technologists to explore the innovations that will drive better outcomes, financially and clinically.
Led by CNBC's anchors and reporters, Healthy Returns hones in on groundbreaking ideas that will transform the health care industry, cutting through the noise and weeding out the "sales pitch." | | Healthy Returns May 12, 2020
New York | |
Post a Comment